Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

Next cohorts for the current trial will be dosing higher. From today's PR:

The ongoing Phase 2, open-label, proof-of-concept trial comprises three sequential cohorts (6 patients per cohort), with progressive dose escalation by cohort—50 mg, 100 mg, and 200 mg, respectively.

CTIX continues to log in success after success. Today's news on Brilacidin has to jolt ones thinking when 2 of the 4 had 100% remission on what is still the LOWER dose level and 50% on the other two. Will be anxious for the NEXT PHASE trial with a LARGER group at a higher dosage.